Kendall Law Group Investigates Martek Biosciences Corporation for Shareholders

Kendall Law Group, led by former federal judge Joe Kendall, is investigating Martek Biosciences Corporation (NASDAQ: MATK) for shareholders in connection with the proposed acquisition by Royal DSM N.V. The national securities firm’s investigation seeks to determine whether Martek and its Board breached their fiduciary duties by entering into the agreement without properly shopping for a deal that would provide better value for shareholders. If you are a Martek shareholder and would like additional information about your rights, contact the Kendall Law Group at 877-744-3728 or by email at [e-mail].

On Dec. 21, 2010, the companies announced the definitive merger agreement under which Martek would be acquired by DSM, in a transaction valued at approximately $1.09 billion. Under the terms of the agreement, Martek stockholders will receive $31.50 in cash for each share of Martek/MATK common stock held. The offer price represents a 35 percent premium to Martek's Dec. 20 closing price. Earlier this month, Martek reported a 36 percent increase in revenues, topping analysts' average estimates. Due to these factors, the firm believes the transaction significantly undervalues the company.

Kendall Law Group was founded by a former federal judge, includes a former United States Attorney, prosecutors and securities lawyers who are experienced in complex securities litigation. The firm has been counsel in numerous merger and acquisition cases nationwide, including some of the largest transactions in the United States.